Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 22165988.
- Also identified by DOI 10.1021/nl2035354 and PMC identifier 3358784.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nanotechnology can provide a critical advantage in developing strategies for cancer management and treatment by helping to improve the safety and efficacy of novel therapeutic delivery vehicles. This paper reports the fabrication of poly(lactic acid-co-glycolic acid)/siRNA nanoparticles coated with lipids for use as prostate cancer therapeutics made via a unique soft lithography particle molding process called Particle Replication In Nonwetting Templates (PRINT). The PRINT process enables high encapsulation efficiency of siRNA into neutral and monodisperse PLGA particles (32-46% encapsulation efficiency). Lipid-coated PLGA/siRNA PRINT particles were used to deliver therapeutic siRNA in vitro to knockdown genes relevant to prostate cancer.
Medical subject headings
- Coated Materials, Biocompatible
- Genetic Therapy
- Nanocapsules
- Prostatic Neoplasms
- RNA, Small Interfering